Skip to main content
THE TREATMENT REGISTRY
Patient journey

This page contains health-related information for reference only. It is not medical advice. Read full disclaimer

ivf fertility

PGT-A

Preimplantation genetic diagnosis is the genetic profiling of embryos prior to implantation, and sometimes even of oocytes prior to fertilization. PGD is considered in a similar fashion to prenatal diagnosis.

By The Treatment Registry

Quick Facts

Price range
Varies by clinic
Recovery
Varies
Sessions
Varies
Category
ivf fertility
Anaesthesia
Varies
Min. stay abroad
Varies
Price Range (International)
Varies by clinic
Average Recovery
Varies
Typical Sessions
Varies
Category
ivf fertility

Overview

PGT-A (preimplantation genetic testing for aneuploidy) is a genetic test performed on embryos created through in-vitro fertilisation to check whether they have a normal number of chromosomes. It is a form of preimplantation genetic screening, testing embryos obtained through IVF or ICSI for aneuploidy, an abnormal number of chromosomes, and it was formally renamed preimplantation genetic diagnosis for aneuploidy (PGD-A) by the Preimplantation Genetic Diagnosis International Society in 2016. Because it requires embryos to examine, PGT-A is an adjunct to assisted reproductive technology and depends on IVF to obtain the eggs or embryos. A small sample of cells is taken by biopsy, generally at the blastocyst stage around day 5 or 6 of development, which has proved less harmful to the embryo than earlier blastomere (cleavage-stage) biopsy. The DNA from the sampled cells is then analysed for chromosome number, so that embryos with the expected chromosome complement can be identified for transfer to the uterus. By screening for aneuploidy, the aim is to help identify embryos with a better chance of a successful pregnancy. The technique is distinct from testing for single-gene (monogenic) diseases: rather than looking for a specific inherited mutation, PGT-A assesses the overall count of chromosomes. It is an invasive procedure that requires serious consideration, and its usefulness can depend on factors such as the woman's age and the stage of development at which the biopsy is performed.

Key Considerations

    Common Risks

    • Damage to the embryo during the biopsy, which can destroy the embryo
    • Loss of embryos during freezing and thawing (about 20% of thawed embryos do not survive)
    • Lower live-birth rate reported with cleavage-stage biopsy in women of advanced maternal age
    • Increased perinatal death rate reported in multiple (twin or higher-order) pregnancies
    Detailed risk profile →

    Credentials a clinic should hold

    Specialty-board certifications and facility-level accreditations relevant to this procedure. Verify on the issuer's public register before booking — most issuers publish a searchable directory.

    • HFEA-licensed fertility centre

      Issuer Human Fertilisation and Embryology Authority (UK)

      UK statutory licence for any clinic providing IVF, ICSI, donor cycles, or embryo storage. The HFEA publishes per-clinic success and adverse-event data.

      Verify on the issuer's register →

    • ESHRE-certified ART centre

      Issuer European Society of Human Reproduction and Embryology

      European fertility-clinic certification covering laboratory standards, embryology QC, and clinical-outcome reporting.

      Verify on the issuer's register →

    Current clinical trials

    Ongoing research studies registered on ClinicalTrials.gov whose intervention involves pgt-a. This is a neutral pointer to public research — not an endorsement, not a recruitment drive, and not medical advice. Trial status changes often; confirm eligibility and current status with the study team via each record.

    Showing 6 recent ongoing studies. Source: ClinicalTrials.gov — all matching trials (U.S. National Library of Medicine, public domain). Retrieved 2026-08-02.

    Recovery Timeline

    Average recovery for PGT-A is 0 days. Individual recovery varies — always follow your surgeon’s specific guidance.

    1. 01Day 0–1

      Immediate

      First 24–48 hours post-procedure. Monitoring, anaesthesia recovery, initial pain management. Most clinics expect you to remain on-site or nearby.

    2. 02Day 2–2

      Early recovery

      Wound care, swelling or bruising peaks, restricted activity. Typical window for follow-up visits and drain removal if applicable. Travel is usually not advised.

    3. 03Day 3–3

      Intermediate recovery

      Gradual return to non-strenuous daily activity. Many international patients fly home during this window. Surgeon may require medical clearance for long-haul travel.

    4. 04Day 4–0

      Full recovery

      Return to full activity, exercise, and work. Final results may still be settling. Final follow-up with local doctor recommended.

    Questions to Ask Your Clinic

      Browse all destinations offering PGT-A →Detailed cost breakdown →

      Frequently Asked Questions

      What is PGT-A?

      PGT-A is preimplantation genetic testing for aneuploidy. It screens embryos created through IVF to check whether they have a normal number of chromosomes, so that embryos with the expected chromosome complement can be selected for transfer.

      How is PGT-A different from PGT-M?

      PGT-A checks the number of chromosomes in an embryo (aneuploidy screening), whereas PGT-M tests for a specific single-gene, or monogenic, disorder. PGT-A counts chromosomes rather than looking for a particular inherited mutation.

      Does PGT-A require IVF?

      Yes. Because embryos are needed for testing, PGT-A is an adjunct to assisted reproductive technology and requires in-vitro fertilisation to obtain the oocytes or embryos to be evaluated.

      When and how is the biopsy done?

      A small sample of cells is taken by biopsy, generally at the blastocyst stage around day 5 or 6 of development. This blastocyst biopsy has proved less harmful to the embryo than earlier cleavage-stage biopsy.

      Why is PGT-A performed?

      It is used to screen embryos for an abnormal number of chromosomes, with the aim of identifying embryos that have a better chance of leading to a successful pregnancy.

      What are the risks to the embryo?

      The biopsy is invasive and can damage or destroy the embryo. There is also loss during freezing and thawing, with about 20% of thawed embryos not surviving, and some studies report poorer outcomes with cleavage-stage biopsy in older women and in multiple pregnancies.

      Conditions treated

      Clinical conditions for which pgt-a is a treatment-ladder option.

      Infertility

      Related Procedures

      Other ivf fertility procedures in our registry

      In Vitro Fertilisation (IVF)Egg FreezingDonor Egg IVFDonor Sperm IVFEmbryo DonationICSIPGT-MFrozen Embryo TransferSurrogacy

      Related tools